GATTI, Davide
 Distribuzione geografica
Continente #
EU - Europa 15.440
NA - Nord America 13.255
AS - Asia 9.867
SA - Sud America 1.481
AF - Africa 184
OC - Oceania 19
Continente sconosciuto - Info sul continente non disponibili 11
Totale 40.257
Nazione #
US - Stati Uniti d'America 13.031
RU - Federazione Russa 5.600
SG - Singapore 4.104
GB - Regno Unito 3.994
CN - Cina 3.252
BR - Brasile 1.217
IT - Italia 1.173
DE - Germania 1.021
HK - Hong Kong 921
SE - Svezia 859
FR - Francia 826
IE - Irlanda 742
FI - Finlandia 597
VN - Vietnam 518
KR - Corea 260
UA - Ucraina 208
IN - India 171
JP - Giappone 149
TR - Turchia 139
CA - Canada 110
AR - Argentina 93
MX - Messico 78
NL - Olanda 74
PL - Polonia 70
BD - Bangladesh 65
ID - Indonesia 62
ES - Italia 53
ZA - Sudafrica 50
BE - Belgio 44
EC - Ecuador 43
IQ - Iraq 42
AT - Austria 36
CO - Colombia 32
CL - Cile 30
TG - Togo 27
BJ - Benin 23
PK - Pakistan 23
UZ - Uzbekistan 23
VE - Venezuela 23
IR - Iran 22
RO - Romania 22
EG - Egitto 20
MA - Marocco 16
CZ - Repubblica Ceca 15
PE - Perù 14
AU - Australia 12
LT - Lituania 12
PY - Paraguay 12
AE - Emirati Arabi Uniti 11
CH - Svizzera 11
KE - Kenya 11
PT - Portogallo 11
SA - Arabia Saudita 10
DZ - Algeria 9
SK - Slovacchia (Repubblica Slovacca) 9
AL - Albania 8
AZ - Azerbaigian 8
BO - Bolivia 8
IL - Israele 8
NP - Nepal 8
A2 - ???statistics.table.value.countryCode.A2??? 7
JO - Giordania 7
AM - Armenia 6
BG - Bulgaria 6
CR - Costa Rica 6
DO - Repubblica Dominicana 6
GE - Georgia 6
GR - Grecia 6
HR - Croazia 6
NZ - Nuova Zelanda 6
UY - Uruguay 6
KW - Kuwait 5
PA - Panama 5
QA - Qatar 5
DK - Danimarca 4
ET - Etiopia 4
JM - Giamaica 4
KG - Kirghizistan 4
LB - Libano 4
LV - Lettonia 4
SN - Senegal 4
TH - Thailandia 4
TN - Tunisia 4
BW - Botswana 3
BY - Bielorussia 3
EE - Estonia 3
HU - Ungheria 3
MK - Macedonia 3
MY - Malesia 3
PH - Filippine 3
PS - Palestinian Territory 3
RS - Serbia 3
SI - Slovenia 3
SV - El Salvador 3
SY - Repubblica araba siriana 3
YE - Yemen 3
BA - Bosnia-Erzegovina 2
BS - Bahamas 2
CY - Cipro 2
EU - Europa 2
Totale 40.206
Città #
Southend 3.616
Singapore 1.933
Moscow 1.830
Chandler 1.642
Jacksonville 1.488
Dallas 1.366
Ashburn 1.031
Hong Kong 903
Woodbridge 787
Dublin 734
Ann Arbor 645
Beijing 518
Houston 482
Wilmington 311
New York 304
Princeton 304
Lawrence 303
Los Angeles 280
Jinan 254
The Dalles 246
Nanjing 217
Shenyang 205
Bologna 193
Redmond 190
Verona 187
Ho Chi Minh City 172
Helsinki 151
Buffalo 150
Munich 140
Tokyo 137
Tianjin 134
Hebei 133
Sindelfingen 123
Hanoi 111
Milan 108
Redondo Beach 107
São Paulo 96
Columbus 95
Changsha 93
Haikou 85
Ningbo 85
Zhengzhou 85
Nanchang 82
Santa Clara 74
Taizhou 72
Hangzhou 70
Boardman 69
Guangzhou 68
Jiaxing 64
San Francisco 63
Warsaw 62
Taiyuan 61
Denver 58
Falkenstein 57
Turku 57
London 56
Seattle 56
Redwood City 45
Washington 44
Hyderabad 43
Norwalk 43
Brussels 42
Brooklyn 41
Chicago 41
Falls Church 40
Rome 40
Fairfield 37
Phoenix 36
Orem 35
Rio de Janeiro 35
Atlanta 34
Fuzhou 33
Jakarta 33
Lanzhou 33
Toronto 33
Boston 32
Montreal 32
Johannesburg 31
Brasília 30
Detroit 30
Düsseldorf 30
Poplar 30
Belo Horizonte 29
Mexico City 29
Seoul 28
Lomé 27
Chennai 26
Dearborn 26
Lancaster 26
Stockholm 26
Council Bluffs 24
Cotonou 23
Manchester 22
Vienna 22
Biên Hòa 21
Da Nang 21
Porto Alegre 21
Tashkent 21
Dongguan 20
Ankara 19
Totale 24.277
Nome #
Teriparatide and denosumab combination therapy and skeletal metabolism 313
[The long term correction of vitamin D deficiency: comparison between different treatments with vitamin D in clinical practice.]. 238
Acute Phase Response After Zoledronic Acid is Associated with Long-Term Effects on White Blood Cells. 228
A case of adult chronic recurrent multifocal osteomyelitis successfully treated with neridronate 228
CD14(++) CD16(-) monocytes are the main source of 11β-HSD type 1 after IL-4 stimulation 226
25-hydroxyvitamin D levels in healthy premenopausal wome: association with bone turnover markers and bone mineral density 224
Long-term effects of amino-bisphosphonates on circulating gamma-delta T cells 219
Association of CTR and COLIA1 alleles with BMD values in peri and postmenopausal women 214
La correzione dell’ipovitaminosi D nel lungo termine: confronto tra diverse modalità di somministrazione di vitamina D nella pratica clinica. 212
The effects of menopause and estrogen replacement therapy on the renal handling of calcium 209
Anti-CCP antibodies and bone 208
[Therapeutic strategies in osteoporosis: whom and when to treat] 205
Bone Metabolism in a Large Cohort of Patients with Systemic Sclerosis 202
Bone metabolism in patients with anorexia nervosa and amenorrhoea 197
Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis 195
Bone mineral density and bone turnover in premenopausal women with rheumatoid arthritis 194
Challenge of diagnosing ANCA-associated vasculitis during COVID-19 pandemic: a missed 'window of opportunity' 194
Type VI Osteogenesis imperfecta: effect of plasma transfusion on bone metabolism 193
Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis 192
Changes in Dkk-1, sclerostin, and RANKL serum levels following discontinuation of long-term denosumab treatment in postmenopausal women 192
Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin. 189
AB0776 18F-Fluoride PET/CT for Detection of Axial Involvement in Ankylosing Spondylitis: 187
Hajdu Cheney Syndrome; report of a novel NOTCH2 mutation and treatment with denosumab 187
[Risk factors for hip fracture in elderly persons]. 187
Amino-Bisphosphonates and Cardiovascular Risk: A New Hypothesis Involving the Effects on Gamma-Delta T Cells 184
A case of mandible Paget’s disease of the bone treated with intravenous neridronate 181
Longitudinal Evaluation of Bone Mineral Density and Bone Metabolism Markers in Patients with Indolent Systemic Mastocytosis Without Osteoporosis 180
Association between non-alcoholic fatty liver disease and bone turnover biomarkers in post-menopausal women with type 2 diabetes 180
Bisphosphonates vs infliximab in ankylosing spondylitis treatment. 179
Bone involvement and osteoporosis in mastocytosis. 176
Concentric left ventricular remodelling is associated with subclinical systolic dysfunction in patients with psoriatic arthritis 176
Clinical profile and outcome of patients with rheumatoid arthritis and abnormally high aortic stiffness 174
Comment on: clinical efficacy of oral alendronate in ankylosing spondylitis: a randomised placebo-controlled trial 173
Is vitamin D deficiency a risk factor for osteonecrosis of the jaw in patients with cancer? A matched case-control study. 173
Treatment with neridronate in children and adolescents with osteogenesis imperfecta: Data from open-label, not controlled, three-year Italian study 169
Association between bone mineral density and serum lipid in men 168
Could γ\δ T-cells explain zoledronic acid adverse events? 168
Circulating Dickkopf-1 and sclerostin in patients with Paget's disease of bone 168
New strategies for the prevention and treatment of systemic and local bone loss; from pathophysiology to clinical application 167
Acute Effects of Glucocorticoid Treatment, TNFα or IL-6R Blockade on Bone Turnover Markers and Wnt Inhibitors in Early Rheumatoid Arthritis: A Pilot Study 167
[Antinflammatory therapy and cardiovascular risk: a consensus view]. 166
18F-fluoride PET/CT for detection of axial involvement in ankylosing spondylitis: correlation with disease activity 166
Teriparatide Treatment in Adult Patients with Osteogenesis Imperfecta Type I. 164
Parathyroid hormone is a determinant of serum Dickkopf-1 levels in ankylosing spondylitis 162
Serum Levels of Tryptase Suggest That Mast Cells Might Have an Antiinflammatory Role in Rheumatoid Arthritis: Comment on the Article by Rivellese et al 161
Allergy and the bone: unexpected relationships 160
Combined Circumferential and Longitudinal Left Ventricular Systolic Dysfunction in Patients with Rheumatoid Arthritis without Overt Cardiac Disease 159
An exploratory study on the role of vitamin D supplementation in improving pain and disease activity in rheumatoid arthritis 159
Prednisone compared to methysprednisolone in the polymyalgia rheumatica treatment 158
Prevalence and incidence of rheumatoid arthritis in Italy. 158
Effects of TNF Inhibitors on Parathyroid Hormone and Wnt Signaling Antagonists in Rheumatoid Arthritis 158
Guidelines for the diagnosis, prevention and management of osteoporosis 158
Rapporti tra sistema immune e metabolismo osseo 156
Denosumab for the Treatment of Mastocytosis-Related Osteoporosis: A Case Series 156
Correction to: Is the exposure to bisphosphonates or osteoporosis the predictor of spinal radiographic progression in ankylosing spondylitis? 156
Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget's disease of bone 154
[Use of nonsteroidal anti-inflammatory drugs in patients with vertebral osteoporotic fractures]. 154
Clinical utility of a wheat-germ precipitation assay for determination of bone alkaline phosphatase concentrations in patients with different metabolic bone diseases 152
Higher Level of Dickkopf-1 is Associated with Low Bone Mineral Density and Higher Prevalence of Vertebral Fractures in Patients with Ankylosing Spondylitis 152
Association Between Short-term Exposure to Environmental Air Pollution and Psoriasis Flare 152
In psoriatic arthritis Dkk-1 and PTH are lower than in rheumatoid arthritis and healthy controls 150
DXA bone mineral density in males: retrospective study in real life. 149
Osteoporosis treatment: why ibandronic acid? 149
Calcio e derivati della vitamina D, terapia sostitutiva, calcitonina, fluoruri, bisfosfonati 149
Artropatie degenerative 148
Distinct effect of zoledronate and clodronate on circulating levels of DKK1 and sclerostin in women with postmenopausal osteoporosis. 147
Cancer in adult patients with inflammatory arthritis is associated with high ascending aortic stiffness and left ventricular hypertrophy and diastolic dysfunction 147
Association between long-term exposure to air pollution and immune-mediated diseases: a population-based cohort study 147
Prevalence and incidence of osteoporotic fractures in patients on long-term glucocorticoid treatment for rheumatic diseases: the Glucocorticoid Induced OsTeoporosis TOol (GIOTTO) study 146
Effects of denosumab on peripheral lymphocyte subpopulations 146
Osteoporosis and fractures in systemic vasculitides: a systematic review and meta-analysis 145
Dose-dependent short-term effects of single high doses of oral vitamin D3 on bone turnover markers 145
Effects of intra-articular clodronate in the treatment of knee osteoarthritis: results of a double-blind, randomized placebo-controlled trial 143
Effects of biological and targeted synthetic DMARDs on bone loss in rheumatoid arthritis 143
Bone health, an often forgotten comorbidity in systemic lupus erythematosus: a comment on the new recommendations 143
Coxibs: a significant therapeutic opportunity. 142
Prevalence of osteoporosis in patients affected by mastocytosis 142
Safety issues and adverse reactions with osteoporosis management 141
Sclerostin and DKK1 in postmenopausal osteoporosis treated with Denosumab. 141
Rituximab increases peripheral natural killer cells in patients with rheumatoid arthritis 140
Effect of hyperandrogenism and menstrual cycle abnormalities on bone mass and bone turnover in young women 139
Correspondence on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry' by Gianfrancesco et al. Disease activity, rather than glucocorticoid therapy, may be associated with COVID-19 severity in patients with rheumatic musculoskeletal diseases 139
Association between increased carotid intima-media thickness and higher serum C-terminal telopeptide of type 1 collagen levels in post-menopausal women with type 2 diabetes 139
Bisphosphonates in the treatment of glucocorticoid-induced osteoporosis: pros 137
Diffuse idiopathic skeletal hyperostosis (DISH) in type 2 diabetes: a new imaging possibility and a new biomarker 137
GH in combination with bisphosphonate treatment in osteogenesis imperfecta 136
Disease Activity and Anticitrullinated Peptide Antibody Positivity Predict the Worsening of Ventricular Function in Rheumatoid Arthritis 136
Association between environmental air pollution and rheumatoid arthritis flares 136
Sclerostin and DKK1 in primary hyperparathyroidism. 135
Osteoporosis: an Independent Determinant of Bone Erosions in Rheumatoid Arthritis? 135
Is the exposure to bisphosphonates or osteoporosis the predictor of spinal radiographic progression in ankylosing spondylitis? 135
Association Between Nonalcoholic Fatty Liver Disease and Reduced Bone Mineral Density in Children: A Meta-Analysis 135
Factors associated with referral for osteoporosis care in men: a real-life study of a nationwide dataset 135
Denosumab, cortical bone and bone erosions in rheumatoid arthritis 134
Association between bone mineral density and serum lipids in men 133
Association between acute exposure to environmental air pollution and fragility hip fractures 132
Bone turnover markers in patients with osteogenesis imperfecta. 132
Insulin-like growth factor-1 is associated with bone formation markers, PTH and bone mineral density in healthy premenopausal women. 132
Prevalence and factors related to left ventricular systolic dysfunction in asymptomatic patients with rheumatoid arthritis. A prospective tissue Doppler echocardiography study 132
In patients with rheumatoid arthritis, Dickkopf-1 serum levels are correlated with parathyroid hormone, bone erosions and bone mineral density 132
Totale 16.581
Categoria #
all - tutte 141.863
article - articoli 137.671
book - libri 0
conference - conferenze 588
curatela - curatele 0
other - altro 212
patent - brevetti 0
selected - selezionate 0
volume - volumi 3.392
Totale 283.726


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.087 0 0 0 0 0 267 61 155 230 18 259 97
2021/20222.363 195 608 27 111 119 113 37 130 169 65 196 593
2022/20234.908 372 430 477 889 434 1.180 55 262 535 46 167 61
2023/20242.537 106 207 229 306 306 415 111 184 43 100 364 166
2024/20256.683 358 448 296 1.026 347 198 306 298 999 579 533 1.295
2025/202612.679 1.371 996 1.473 3.206 4.687 946 0 0 0 0 0 0
Totale 40.805